CDER Industry Assistance Resources (13of15) REdI – May 29-30, 2019

Автор: U.S. Food and Drug Administration

Загружено: 2020-03-27

Просмотров: 661

Описание: CDER Office of Communications’ Renu Lal covers the broad array of learning products and other resources available from CDER’s Small Business and Industry Assistance program.

Learn more at https://www.fda.gov/drugs/cder-small-...

_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Visit https://www.fda.gov/cdersbia and https://www.fda.gov/cdersbialearn for news and a repository of training activities.

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367
LinkedIn: / cder-small-business-and-industry-assistance
Twitter: / fda_drug_info
CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...

CDER Industry Assistance Resources (13of15) REdI – May 29-30, 2019

Доступные форматы для скачивания:

Скачать видео

Информация по загрузке:

Скачать аудио

Похожие видео

CMC - NDA requirements and Common Pitfalls of BLAs (14of15) REdI – May 29-30, 2019

CMC - NDA requirements and Common Pitfalls of BLAs (14of15) REdI – May 29-30, 2019

Medical Device Quality Management System Regulation Risk Management

Medical Device Quality Management System Regulation Risk Management

Framework for FDA’s Real-World Evidence Program – Mar 15, 2019

Framework for FDA’s Real-World Evidence Program – Mar 15, 2019

eCTD Submissions of Promotional Labeling and Advertising Materials

eCTD Submissions of Promotional Labeling and Advertising Materials

FDA Direct: Catching Up on Agency Reforms

FDA Direct: Catching Up on Agency Reforms

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

NDA and BLA Application Review Process (6of15) REdI Annual Conference – May 29-30, 2019

NDA and BLA Application Review Process (6of15) REdI Annual Conference – May 29-30, 2019

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA Direct: FDA Awards Six National Priority Vouchers

FDA Direct: FDA Awards Six National Priority Vouchers

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S05 - (PV): Future of...

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S05 - (PV): Future of...

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Public Meeting: Reauthorization of the Biosimilar User Fee Act

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

November 13, 2025: Pediatric Advisory Committee Meeting (PAC)

November 13, 2025: Pediatric Advisory Committee Meeting (PAC)